James Hartley. Aberrant Splicing Factor SF3A2 as a Prognostic Biomarker and Therapeutic Target in Colorectal Cancer: Interplay with Immune Infiltration and Natural Product Intervention. ijmsdh [Internet]. 2026 Sep. 17 [cited 2026 Sep. 18];12(09):176-81. Available from: https://www.ijmsdh.org/index.php/ijmsdh/article/view/743